Clinical Trial Update: Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating safety and immunogenicity of an oral replicating Ad26-vectored HIV-1 vaccine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Ad26-vectored HIV-1 vaccine (oral, replicating)

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: HIV | Phase 1 | Status: COMPLETED